Tregalizumab
Modify Date: 2024-04-03 11:17:51
Tregalizumab structure
|
Common Name | Tregalizumab | ||
|---|---|---|---|---|
| CAS Number | 1207446-68-1 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TregalizumabTregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies[1][2][3]. |
| Name | Tregalizumab |
|---|
| Description | Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
CD4[1][2][3]. |
| In Vitro | Tregalizumab 能够激活调节性 T 细胞的抑制能力[1]。 Tregalizumab 减少用破伤风类毒素刺激 (以剂量依赖性方式) 分离的 PBMC 的增殖和细胞因子分泌[1]。 Tregalizumab (0-30 µg/mL; 18 h) 处理 PBMC 诱导 T 细胞的 CD4 下调[2]。 Tregalizumab 主要诱导炎症部位的 CD4 下调[2]。 Cell Viability Assay[2] Cell Line: PBMC cells Concentration: 0-30 µg/mL Incubation Time: 18 h Result: Induced CD4 down-modulation of T cells. |
| References |
| No Any Chemical & Physical Properties |